Vector mediated immunoprophylaxis

Published on May 28, 2015   31 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

My name is Bruce Schnepp, and I'm from the Children's Hospital of Philadelphia. This lecture is titled Vector Mediated Immunoprophylaxis, which is a fairly new concept in vaccine development. I've been in this area of study for over 15 years, using this technology for the development of an HIV vaccine.
For this lecture, I'm going to focus on our efforts to use vector mediated immunoprophylaxis as an HIV vaccine. In our case, vector mediated immunoprophylaxis simply means that we're trying to prevent disease by providing antibodies to block infection. A unique twist for us is how we are delivering the antibodies. So first, I'll introduce you to HIV and sort of where we currently are with progress towards a vaccine. And I know that there are other lectures in this course that discuss HIV in more detail, so I'll keep this part brief. I'll then introduce the concept of vector mediated immunoprophylaxis and the mechanics of how it works, with emphasis on how it differs from other conventional vaccine strategies. I'll then spend some time discussing our path forward, using this strategy to develop an HIV vaccine. This is sort of a case study that takes you through some key animal studies on mice and monkeys that ultimately led us to clinical trial on humans. Finally, I'll discuss the future of vector mediated immunoprophylaxis with applications to other difficult diseases and end with highlighting a few of the limitations of this strategy.